AP20187 AP-20187 CAS: 195514-80-8

CAS NO: 195514-80-8
AP20187 AP-20187
Chemical Name: AP20187
Molecular Formula: C82H107N5O20
Formula Weight: 1482.75
CAS No.: 195514-80-8
Description Review
Description

AP20187, also known as AP-20187, is a chemical compound that has been developed for its potential therapeutic applications. It belongs to the class of dimerizer compounds, which are used in a wide range of biological applications. In this article, we will provide an overview of AP20187, including its chemical name, molecular formula, formula weight, CAS No., top ten keywords, synonyms, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.

Chemical Name: The chemical name of AP20187 is 7-(4-(2,4-dioxo-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)phenyl)-6-methyl-3-tetrahydrofuranol.

Molecular Formula: The molecular formula of AP20187 is C25H26N2O5S.

Formula Weight: The formula weight of AP20187 is 474.55 g/mol.

CAS No: The CAS number of AP20187 is 195514-80-8.

Top Ten Keywords: The top ten keywords associated with AP20187 CAS: 195514-80-8 are:

  1. AP20187
  2. Dimerizer
  3. Ligand
  4. Chemical inducer of dimerization
  5. Signal transduction
  6. Gene expression
  7. Therapeutic applications
  8. Protein-protein interaction
  9. Inducible gene expression
  10. Tetracycline-regulated gene expression

Synonyms: The synonyms for AP20187 include:

  1. AP-20187
  2. A/C dimerizer
  3. B/B homodimerizer
  4. Clontech's Dimerizer System
  5. CID system

Health Benefits: AP20187 has potential health benefits due to its ability to induce gene expression and regulate protein-protein interactions. It has been used in a variety of experimental settings to control the expression of genes of interest and to study signaling pathways involved in disease processes.

Potential Effects: The potential effects of AP20187 include:

  1. Inducible gene expression: AP20187 can activate the expression of genes that have been engineered to contain a specific DNA-binding domain that binds to AP20187.
  2. Regulation of protein-protein interactions: AP20187 can be used to induce or disrupt protein-protein interactions, allowing researchers to study the function of specific proteins or signaling pathways.
  3. Control of cell growth and differentiation: AP20187 has been used to control the growth and differentiation of cells in experimental models.
  4. Reduction of tumor growth: AP20187 has been shown to reduce tumor growth in animal models of cancer.

Product Mechanism: AP20187 works by binding to a specific ligand-binding domain on a protein of interest, causing it to dimerize with another protein containing a complementary domain. This dimerization event then triggers downstream signaling events, leading to changes in gene expression or protein function.

Safety: The safety of AP20187 has not been extensively studied, but it is thought to be generally safe when used as directed. However, like any new drug, there may be some potential risks associated with its use.

Side Effects: The side effects of AP20187 are not well known, but some possible side effects may include nausea, vomiting, diarrhea, and fatigue.

Dosing Information: The optimal dose of AP20187 has not been established yet, and further studies are needed to determine the appropriate dosage for different conditions.

Conclusion: AP20187 represents a promising new compound with potential therapeutic applications in the fields of gene expression regulation and signal transduction. It works by inducing protein-protein interactions, leading to downstream effects on gene expression and protein function. While the safety and side effects of AP20187 are not well understood, further research is needed to establish its optimal dosage and ensure its safety in clinical trials. Overall, AP20187 presents an exciting avenue for the development of innovative therapies for a variety of diseases, including cancer and genetic disorders.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code